Peking University People's Hospital: Leukemia trials

The registry lists 24 Leukemia studies with Peking University People's Hospital as lead sponsor. 12 are open to participants now and 0 have results posted.

Early Phase 1 1Phase 1 3Phase 2 6Phase 3 4No phase 12(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Thiotepa Combined With Busulfan and Fludarabine Conditioning Regimen for Haploidentical Hematopoietic Stem Cell Transplantation in Elderly Patients With High-Risk Acute Myeloid LeukemiaRecruitingNCT06869265Phase 2
• Interferon-alpha As Maintenance Therapy for Favorable-risk Acute Myeloid LeukemiaRecruitingNCT06802718Phase 3
• An Exploratory Study of RD140 Injection in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell LeukemiaNot yet recruitingNCT06655519Phase 1
• Bridging Allogeneic Hematopoietic Stem Cell Transplantation or Not After CD19 CAR - T (S1904) Cell Therapy for r/r B-cell Acute Lymphoblastic LeukemiaRecruitingNCT06581081Not applicable
• The Efficacy and Safety of Third-generation TKIs Combined With Azacitidine and Bcl-2 Inhibitor in Patients With CML-MBPRecruitingNCT06390306
• MRD Response-adapted Allo-HSCT for Adverse-risk AMLRecruitingNCT06301425Not applicable
• Off-the-shelf CD123 CAR-NK for R/R AMLRecruitingNCT06201247Early Phase 1
• Clinical Study of Venetoclax Combined With CAG in the Treatment of Refractory/Relapsed Acute Myeloid LeukemiaRecruitingNCT05918198Phase 2
• Clinical Registration Study of Haplo-HSCT for Elderly Patients With Acute Leukemia/ Myelodysplastic SyndromeRecruitingNCT05902416
• Optimum Induction Therapy of Low-risk APLRecruitingNCT05832320Not applicable
• Decitabine Plus mBU/CY for High Risk Acute Leukemia With MRD Pre-HSCTRecruitingNCT03793517Phase 2/3
• Haploidentical Peripheral Blood Stem Cell Transplantation for Acute LeukemiaRecruitingNCT03756675
• NAC for Promoting Hematopoietic Recovery in Patients With Acute Myeloid Leukemia After ChemotherapyActive, not recruitingNCT06024031Phase 2
• LILRB4 STAR-T Cells in the Treatment of R/R AML/CMMLCompletedNCT05548088Phase 1
• NK Cell Infusion for Patients With Acute Myeloid LeukemiaStatus unknownNCT04221971Phase 1
• Randomized,International Multi-center Clinical Trial of RIF Plus RA for Non-high-risk APLStatus unknownNCT04175587Phase 3
• Decitabine Plus mBU/CY Preconditioning for Relapse/Refractory Acute LeukemiaStatus unknownNCT03799224Phase 2/3
• C-CAR011 Treatment in Subjects With ALL After HSCTStatus unknownNCT03327285Not applicable
• Chemotherapy and DLI for Prevention of Second Relapse in Patients With Relapsed Acute Leukemia After AllotransplantStatus unknownNCT03297528Phase 2
• Interferon-α Prevents Leukemia Relapse of AML Patients After TransplantationWithdrawnNCT03121079Not applicable
• Treatment of Chronic Lymphocytic LeukemiaStatus unknownNCT02757586
• Randomized Trial of Mobilized Blood/Marrow Versus Blood TransplantWithdrawnNCT01617473Not applicable
• Efficiency Study of Low Dose of IL-2 to Prevent Relapse in Standard Risk Leukemia After TransplantationTerminatedNCT01517347Not applicable
• New Therapy for Advanced Stage Leukemia After Stem Cell TransplantationCompletedNCT01455272Not applicable